249 related articles for article (PubMed ID: 24332016)
21. Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration.
Wen Z; Liu H; Li M; Li B; Gao W; Shao Q; Fan B; Zhao F; Wang Q; Xie Q; Yang Y; Yu J; Qu X
Oncogene; 2015 Mar; 34(10):1241-52. PubMed ID: 24662827
[TBL] [Abstract][Full Text] [Related]
22. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
23. Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis.
Xia H; Li S; Li X; Wang W; Bian Y; Wei S; Grove S; Wang W; Vatan L; Liu JR; McLean K; Rattan R; Munkarah A; Guan JL; Kryczek I; Zou W
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32780724
[TBL] [Abstract][Full Text] [Related]
24. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.
Akutagawa N; Nishikawa A; Iwasaki M; Fujimoto T; Teramoto M; Kitajima Y; Endo T; Shibuya M; Kudo R
Jpn J Cancer Res; 2002 Jun; 93(6):644-51. PubMed ID: 12079512
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer.
Liu L; Ge D; Ma L; Mei J; Liu S; Zhang Q; Ren F; Liao H; Pu Q; Wang T; You Z
J Thorac Oncol; 2012 Jul; 7(7):1091-100. PubMed ID: 22534817
[TBL] [Abstract][Full Text] [Related]
26. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
Zhu Q; Wu X; Wu Y; Wang X
Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells
Brauneck F; Oliveira-Ferrer L; Muschhammer J; Sturmheit T; Ackermann C; Haag F; Schulze Zur Wiesch J; Ding Y; Qi M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Wellbrock J
Front Immunol; 2023; 14():1250258. PubMed ID: 37876933
[TBL] [Abstract][Full Text] [Related]
28. TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells.
Bellora F; Castriconi R; Dondero A; Pessino A; Nencioni A; Liggieri G; Moretta L; Mantovani A; Moretta A; Bottino C
Eur J Immunol; 2014 Jun; 44(6):1814-22. PubMed ID: 24510590
[TBL] [Abstract][Full Text] [Related]
29. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages.
Tai SK; Chang HC; Lan KL; Lee CT; Yang CY; Chen NJ; Chou TY; Tarng DC; Hsieh SL
J Immunol; 2012 Mar; 188(5):2464-71. PubMed ID: 22287720
[TBL] [Abstract][Full Text] [Related]
30. Alternative activation of macrophages in human peritoneum: implications for peritoneal fibrosis.
Bellón T; Martínez V; Lucendo B; del Peso G; Castro MJ; Aroeira LS; Rodríguez-Sanz A; Ossorio M; Sánchez-Villanueva R; Selgas R; Bajo MA
Nephrol Dial Transplant; 2011 Sep; 26(9):2995-3005. PubMed ID: 21324976
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
Nash MA; Lenzi R; Edwards CL; Kavanagh JJ; Kudelka AP; Verschraegen CF; Platsoucas CD; Freedman RS
Clin Exp Immunol; 1998 May; 112(2):172-80. PubMed ID: 9649178
[TBL] [Abstract][Full Text] [Related]
32. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.
Prat M; Coulson K; Blot C; Jacquemin G; Romano M; Renoud ML; AlaEddine M; Le Naour A; Authier H; Rahabi MC; Benmoussa K; Salon M; Parny M; Delord JP; Ferron G; Lefèvre L; Couderc B; Coste A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586764
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer.
Geller MA; Bui-Nguyen TM; Rogers LM; Ramakrishnan S
Int J Gynecol Cancer; 2010 Aug; 20(6):918-25. PubMed ID: 20683396
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of
Jiang S; Yang Y; Zhang Y; Ye Q; Song J; Zheng M; Li X
Dis Markers; 2022; 2022():9719671. PubMed ID: 35186171
[TBL] [Abstract][Full Text] [Related]
35. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
[TBL] [Abstract][Full Text] [Related]
36. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
37. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.
Khan ANH; Emmons TR; Magner WJ; Alqassim E; Singel KL; Ricciuti J; Eng KH; Odunsi K; Tomasi TB; Lee K; Abrams SI; Mesa C; Segal BH
Cancer Immunol Immunother; 2022 Oct; 71(10):2355-2369. PubMed ID: 35166871
[TBL] [Abstract][Full Text] [Related]
38. Astragaloside IV antagonizes M2 phenotype macrophage polarization-evoked ovarian cancer cell malignant progression by suppressing the HMGB1-TLR4 axis.
Wang X; Gao S; Song L; Liu M; Sun Z; Liu J
Mol Immunol; 2021 Feb; 130():113-121. PubMed ID: 33308900
[TBL] [Abstract][Full Text] [Related]
39. Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients.
Chu CS; Woo EY; Toll AJ; Rubin SC; June CH; Carroll RG; Schlienger K
Clin Immunol; 2002 Mar; 102(3):291-301. PubMed ID: 11890716
[TBL] [Abstract][Full Text] [Related]
40. GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth.
Luo C; Shibata K; Suzuki S; Kajiyama H; Senga T; Koya Y; Daimon M; Yamashita M; Kikkawa F
Oncol Rep; 2014 Sep; 32(3):913-21. PubMed ID: 24992906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
